Galectin Therapeutics (NASDAQ:GALT – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Wednesday. Separately, HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of Galectin Therapeutics in a report on Tuesday, April 9th. Check Out Our Latest […]